+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2027

  • PDF Icon

    Report

  • 49 Pages
  • February 2022
  • Region: Global
  • GlobalData
  • ID: 5562917
In Childhood Epilepsy Gamma-aminobutyric acid type A receptor (GABA(A) receptor) is a major focus of drug developers. There are 27 drugs in the pipeline with 79% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The increasing uptake of recently launched therapies will drive the market's growth, but wide availability of low cost generic products is expected to limit the uptake of branded therapies.

This reports provides a data-driven overview of the current and future competitive landscape in childhood epilepsy therapeutics.

Scope


  • The publisher's Childhood Epilepsy: Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

The accompanying Excel file includes the following datasets -
  • Marketed products exported from the publisher's Pharmaceutical Intelligence Center
  • Pipeline-stage products exported from the publisher's Pharmaceutical Intelligence Center
  • Upcoming catalysts in the childhood epilepsy market exported from the Catalyst Calendar on the publisher's Pharmaceutical Intelligence Center
  • A list of patent expiry dates for childhood epilepsy products

Reasons to Buy


  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global childhood epilespsy market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global childhood epilepsy market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
4.2 Marketed Drug Profiles
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.4 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
8.1 Key Twitter Chatter
8.2 Top Branded Websites
8.3 Trust Flow and Citation Flow
9 Appendix
9.1 Methodology
9.2 About the Authors
9.3 About the Publisher
9.4
9.5 Disclaimer